• Finance Tax Investment

CEO Update | 9 May 2022

Congratulations to Omass Therapeutics for raising $100 million in the Series B financing round, as well as two BIA member companies - Scotland-based EnteroBiotix and Solvemed group, who were featured in Forbes ‘30 under 30 Europe’ Science and Healthcare Edition for 2022. We are also glad to see engineering biology receive £20.6 million in investment from UK Research and Innovation (UKRI). Read more on IP TRIPS Waiver, update on Northern Ireland and BBSRC Business and Academia Prosperity Partnership.

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncona, Oxford Science Enterprises, and Oxford University also participating. Investment will advance OMass’s portfolio of novel drugs against highly-validated, yet intractable or inadequately drugged, membrane- and complex-bound proteins towards the clinic.

Guest blog: Cambridge Innovation Capital Fund II

Guest blog by Andrew Williamson, Managing Partner of Cambridge Innovation Capital (CIC) about the oversubscribed second fund, Fund II. CIC was founded to improve the success rate of businesses originating from the University of Cambridge and the broader Cambridge ecosystem, to encourage more academics and entrepreneurs to build businesses. Read more about the six companies which benefitted from being part of the fund.

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

Cancer Research UK, the world’s largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach to driving innovation in the development of new treatments for patients, by combining the power of academia and industry.

CEO Update | 25 April 2022

It is great to see our ecosystem back out and about in person this Spring – and especially to be joined by 200 colleagues from across the biotech and life sciences sector at our London Regional event last week. The discussion on funding alternatives to IPO for scaling biotechs was both insightful and inspiring and provoked lots more conversations in the vibrant networking that followed. Read on for updates on WuXi healthcare forum, just published BIA quarterly influence report, Valneva approval and more...

Making the Innovative Medicines Fund work for the most innovative new medicines

The ultimate aim of drug development is for patients to access lifesaving and life-enhancing new medicines, but for many of the most innovative new medicines, securing access for NHS patients is a long and difficult process. One of the most promising new areas of medicine is cell and gene therapies, which have potential to address complex diseases, including many rare diseases for which there are no effective treatments. However, these treatments face challenges in securing patient access because of high up-front cost and uncertainty about long-term outcomes.

CEO Update | 11 April 2022

Last week, we released new data showing that UK biotech companies continue to demonstrate they command the confidence of global venture capital(VC) investors with £453m raised in the first quarter of 2022. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth. The data was covered in this weekend’s Sunday Times with analysis from our Head of Policy and Public Affairs, Dr Martin Turner.

Strong venture capital quarter for UK biotech as sector advances in all quarters

The UK is the place in the world where life science investment works hardest UK biotech companies continue to demonstrate they command the confidence of global venture capital (VC) investors with £453m raised in the first quarter of 2022, new data published by the BioIndustry Association (BIA) and Clarivate shows. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth.

CEO Update | 4 April 2022

On Thursday last week the Government announced a £15.9 million investment into Croda’s Staffordshire facility to increase the UK’s capacity of lipids, which are used to create lipid nanoparticles which are a crucial component of mRNA vaccines and therapies. Read more about Canary Wharf becoming life science hub, update from the Royal Society Science of COVID-19 conference, and our response to Biological Security Strategy and House of Lords Science and Technology committee on UK science and technology strategy.

Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing

Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines. This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs